You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 269 No. 17, May 5, 1993 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (87)
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

A Controlled Trial of HA-1A in a Canine Model of Gram-negative Septic Shock

Zenaide M. N. Quezado, MD; Charles Natanson, MD; David W. Ailing, MD, PhD; Steven M. Banks, PhD; Cezar A. Koev, MD; Ronald J. Elin, MD, PhD; Jeanette M. Hosseini; John D. Bacher, VMD; Robert L. Danner, MD; William D. Hoffman, MD

JAMA. 1993;269(17):2221-2227.


Abstract

Objectvie.
—To investigate the therapeutic efficacy and microbiological and physiological effects of a human IgM monoclonal antibody (HA-1 A) directed against the lipid A component of endotoxin in a canine model of sepsis that simulates the cardiovascular abnormalities of human septic shock.

Design.
—Blinded, placebo-controlled 28-day trial.

Interventions.
—Purpose-bred beagles were implanted with an intraperitoneal clot infected with Escherichia coli O111:B4. At clot placement, animals received HA-1A (10 mg.kg-1), control human IgM antibody (10 mg.kg-1), or control human serum albumin intravenously. All animals were given antibiotic and fluid therapy.

Measures.
—Survival and microbiological and physiological events.

Results.
—Only two (15%) of 13 animals in the HA-1A group, compared with eight (57%) of 14 control animals (combined control human IgM antibody and control human serum albumin groups) (P=.05), survived 28 days. At 24 hours, the HA-1A group had lower mean arterial pressure (P=.04) and cardiac index (P=.004) and higher lactate levels (P=.05) compared with the combined-controls group. In addition, these parameters in the HA-1A group were significantly more predictive of death. The HA-1 A and combined-controls groups had similar significant increases in the level of endotoxemia and bacteremia. Studies of toxic effects showed no harmful effects of control human IgM antibody in infected animals or HA-1 A in noninfected animals.

Conclusion.
—In a canine model of E coli sepsis, HA-1 A did not alter levels of bacteremia or endotoxemia and actually decreased survival. If these data are relevant to human septic shock, HA-1 A therapy should be limited until the conditions under which this monoclonal antibody has beneficial or deleterious effects are more completely defined.

(JAMA. 1993;269:2221-2227)



Author Affiliations

From the Department of Critical Care Medicine (Drs Quezado, Natanson, Alling, Banks, Koev, Danner, and Hoffman), Department of Clinical Pathology (Dr Elin and Ms Hosseini), and the Veterinary Resources Program, National Center for Research Resources (Dr Bacher), National Institutes of Health, Bethesda, Md.


Footnotes

Preliminary data were published in abstract form in Clinical Research. 1992;40:286.

Reprint requests to Department of Critical Care Medicine, National Institutes of Health, Bldg 10, Room 7D43, 9000 Rockville Pike, Bethesda, MD 20892 (Dr Quezado).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Apoptotic Cells Protect Mice against Lipopolysaccharide-Induced Shock
Ren et al.
J. Immunol. 2008;180:4978-4985.
ABSTRACT | FULL TEXT  

A canine model of septic shock: balancing animal welfare and scientific relevance
Minneci et al.
Am. J. Physiol. Heart Circ. Physiol. 2007;293:H2487-H2500.
ABSTRACT | FULL TEXT  

Protection from endotoxemia by adenoviral-mediated gene transfer of human bactericidal/permeability-increasing protein
Alexander et al.
Blood 2004;103:93-99.
ABSTRACT | FULL TEXT  

Anti-Lipid A Monoclonal Antibody Centoxin (HA-1A) Binds to a Wide Variety of Hydrophobic Ligands
Helmerhorst et al.
Infect. Immun. 1998;66:870-873.
ABSTRACT | FULL TEXT  

Relationship of Preoperative Antiendotoxin Core Antibodies and Adverse Outcomes Following Cardiac Surgery
Bennett-Guerrero et al.
JAMA 1997;277:646-650.
ABSTRACT  

Review: Bacterial endotoxin and the human monoclonal antibody HA-IA: specificity, potential mechanisms of action, and limits to its effectiveness
Lagrange et al.
Innate Immunity 1995;2:371-386.
ABSTRACT  

Looking Back on HA-1A
Quezado et al.
Arch Intern Med 1994;154:2393-2393.
ABSTRACT  

The French National Registry of HA-1A (Centoxin) in Septic Shock: A Cohort Study of 600 Patients
The National Committee for the Evaluation of Cento
Arch Intern Med 1994;154:2484-2491.
ABSTRACT  

Projected Impact of Monoclonal Anti-Endotoxin Antibody Therapy
Bates and Lee
Arch Intern Med 1994;154:1241-1249.
ABSTRACT  

Minireview: Therapeutic intervention in sepsis with antibody to endotoxin: is there a future?
Cross and Opal
Innate Immunity 1994;1:57-69.
ABSTRACT  

MORE EVIDENCE AGAINST THE EFFECTIVENESS OF HA-1A
JWatch General 1993;1993:7-7.
FULL TEXT  

The Search for a Magic Bullet to Fight Sepsis
Bone
JAMA 1993;269:2266-2267.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.